Stock listing
ASX:CHM Chimeric Therapeutics Limited Share Price
Home listing (ASX) of Chimeric Therapeutics Limited
Follow Chimeric Therapeutics Limited into a list and get an email when it puts out news.
Share price · ASX:CHM
$0.0030 AUD 0.0000 (0.0%)
Close on Nov 19, 2026
- Day range
- $0.0030 – $0.0030 AUDNov 19, 2026
- Market cap
- $442,386 AUDAt the close on Nov 19, 2026 · price × 147.5M shares outstanding
- 52-week range
- $0.0030 – $0.4000 AUDLowest and highest trades, Nov 20, 2025 – Nov 19, 2026
- Traded on an average day
- $11,148 AUDMedian day 0 shares · 37 days with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ASX:CHM · Home | $0.0030 AUD | 0.0000 (0.0%) | — | $0.0030 | $0.0030 | $0.0030 | $0.0030 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 19, 2026 – Nov 19, 2026 · ASX:CHM · AUD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | -0.0020 | -40.0% | $0.0040 | $0.0040 | $0.0030 | 25,127,056 | |
| $0.0050 | +0.0010 | +25.0% | $0.0040 | $0.0050 | $0.0040 | 905,234 | |
| $0.0040 | -0.0010 | -20.0% | $0.0050 | $0.0050 | $0.0040 | 780,031 | |
| $0.0050 | +0.0010 | +25.0% | $0.0040 | $0.0050 | $0.0040 | 511,864 | |
| $0.0040 | -0.0010 | -20.0% | $0.0050 | $0.0050 | $0.0040 | 3,645,258 | |
| $0.0050 | -0.0010 | -16.7% | $0.0060 | $0.0060 | $0.0050 | 13,378,075 | |
| $0.0060 | -0.0010 | -14.3% | $0.0070 | $0.0070 | $0.0060 | 1,350,110 | |
| $0.0070 | +0.0010 | +16.7% | $0.0060 | $0.0075 | $0.0060 | 1,431,073 | |
| $0.0060 | 0.0000 | 0.0% | $0.0060 | $0.0060 | $0.0060 | 150,611 | |
| $0.0060 | 0.0000 | 0.0% | $0.0060 | $0.0060 | $0.0060 | 0 | |
| $0.0060 | 0.0000 | 0.0% | $0.0060 | $0.0070 | $0.0060 | 935,871 | |
| $0.0060 | -0.0010 | -14.3% | $0.0060 | $0.0060 | $0.0060 | 21,448 | |
| $0.0070 | -0.0010 | -12.5% | $0.0080 | $0.0080 | $0.0070 | 67,857 | |
| $0.0080 | 0.0000 | 0.0% | $0.0080 | $0.0080 | $0.0080 | 108,734 | |
| $0.0080 | +0.0010 | +14.3% | $0.0070 | $0.0080 | $0.0070 | 66,240 | |
| $0.0070 | 0.0000 | 0.0% | $0.0070 | $0.0070 | $0.0070 | 1,231,577 | |
| $0.0070 | +0.0010 | +16.7% | $0.0060 | $0.0070 | $0.0060 | 1,760,880 | |
| $0.0060 | -0.0020 | -25.0% | $0.0090 | $0.0090 | $0.0060 | 5,378,282 | |
| $0.0080 | -0.0030 | -27.3% | $0.0110 | $0.0110 | $0.0080 | 3,354,346 | |
| $0.0110 | -0.0010 | -8.3% | $0.0110 | $0.0110 | $0.0110 | 2,858 | |
| $0.0120 | 0.0000 | 0.0% | $0.0120 | $0.0120 | $0.0110 | 17,546 | |
| $0.0120 | +0.0010 | +9.1% | $0.0110 | $0.0120 | $0.0110 | 43,133 | |
| $0.0110 | +0.0020 | +22.2% | $0.0090 | $0.0110 | $0.0090 | 2,033,701 | |
| $0.0090 | -0.0010 | -10.0% | $0.0100 | $0.0100 | $0.0090 | 5,414,073 | |
| $0.0100 | -0.0010 | -9.1% | $0.0110 | $0.0115 | $0.0100 | 2,011,389 | |
| $0.0110 | -0.0020 | -15.4% | $0.0130 | $0.0140 | $0.0110 | 1,873,645 | |
| $0.0130 | -0.0020 | -13.3% | $0.0160 | $0.0160 | $0.0130 | 2,466,882 | |
| $0.0150 | -0.0050 | -25.0% | $0.0180 | $0.0180 | $0.0150 | 2,673,341 | |
| $0.0200 | +0.0020 | +11.1% | $0.0190 | $0.0200 | $0.0170 | 4,427,792 | |
| $0.0180 | -0.0010 | -5.3% | $0.0200 | $0.0200 | $0.0180 | 1,747,308 | |
| $0.0190 | -0.0160 | -45.7% | $0.0180 | $0.0220 | $0.0140 | 8,864,321 |
Splits
1 split · ASX:CHM · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-100 | Consolidation |
- Ticker
- ASX:CHM
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- ASX
- Currency
- AUD
What changed lately
Latest news release · Oct 30, 2026
Notification of cessation of securities - CHM
Latest deck · Jul 28, 2026
Investor Presentation (July 2026)
Investor deck · 19 slides
Latest news
Notification of cessation of securities - CHM
Oct 30, 2026
Closed $0.0030 (0.0%) on Oct 30, 2026
Notice of Annual General Meeting/Proxy Form
Oct 29, 2026
Closed $0.0030 (0.0%) on Oct 30, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
Oct 29, 2026
Closed $0.0030 (0.0%) on Oct 30, 2026
Ceasing to be a substantial holder for CHM
Oct 8, 2026
Closed $0.0030 (0.0%) on Oct 9, 2026
Notice of initial substantial holder for CHM
Oct 6, 2026
Closed $0.0030 (0.0%) on Oct 7, 2026
Final Director's Interest Notice - LR
Oct 5, 2026
Closed $0.0030 (0.0%) on Oct 6, 2026
Final Director's Interest Notice - BG
Oct 5, 2026
Closed $0.0030 (0.0%) on Oct 6, 2026
Initial Director's Interest Notice - RM
Oct 5, 2026
Closed $0.0030 (0.0%) on Oct 6, 2026
FY2026 Annual Report, creditor update and Board changes
Sep 30, 2026
Closed $0.0030 (0.0%) on Oct 1, 2026
Application for quotation of securities - CHM
Sep 29, 2026
Closed $0.0030 (-40.0%) on Sep 30, 2026
Chimeric Therapeutics Limited on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 36 in the last 12 months · 129 in all · newest Oct 30, 2026 · oldest 2021
- Decks
- 23 decks · latest Jul 28, 2026
Where Chimeric Therapeutics Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ASX:CHM · Home listing · This page | ASX | Australia | AUD |
| OTC:CHMMF | OTC | United States | USD |
Valuation
EV/sales −0.1× against a median of 0.3×: the lowest of 3 Biotechnology companies shown. Statements: Year to Jun 30, 2025 · price Nov 19, 2026
- Enterprise value
- −$332,667 AUD
- P/E
- Loss
- EV/sales
- −0.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.2×
- Gross margin
- 78.7%
- Operating margin
- −380.8%
- Net margin
- −262.8%
- Debt to equity
- 2.5×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Chimeric Therapeutics Limited · ASX:CHM | US$292,816 | −US$220,193 | n/a | −0.1× | n/a | 0.2× | −262.8% | 2.5× | n/a |
| Mushrooms, Inc. · OTC:MSRM | US$539,339 | US$564,177 | n/a | n/a | n/a | n/a | n/a | n/a | 1.24 |
| Jaguar Health, Inc. · NASDAQ:JAGX | US$527,406 | −US$1.48M | n/a | −0.1× | n/a | 0.0× | −181.8% | 0.2× | 3.75 |
| Altamira Therapeutics Ltd. · OTC:CYTOF | US$404,655 | US$400,900 | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 0.64 |
| NKGen Biotech Inc. · OTC:NKGN | US$391,807 | US$38.58M | n/a | n/a | n/a | n/a | n/a | n/a | 0.88 |
| Vaxil Bio Ltd. · TSXV:VXL | US$319,500 | −US$4,070 | 1.2× | n/a | n/a | 0.4× | n/a | 0.0× | -0.16 |
| CERo Therapeutics Holdings, Inc. · OTC:CERO | US$265,035 | −US$190,890 | n/a | n/a | n/a | n/a | n/a | n/a | 1.47 |
| CDT Equity Inc. · NASDAQ:CDT | US$234,109 | −US$1.49M | n/a | n/a | n/a | 0.0× | n/a | 0.0× | 1.14 |
| GlucoTrack, Inc. · NASDAQ:GCTK | US$217,049 | −US$887,951 | n/a | n/a | n/a | n/a | n/a | n/a | 1.73 |
| Regen BioPharma, Inc. · OTC:RGBP | US$167,528 | US$167,289 | n/a | 0.7× | n/a | n/a | −501.4% | n/a | 1.20 |
| CNBX Pharmaceuticals Inc. · OTC:CNBX | US$160,577 | US$151,090 | n/a | n/a | n/a | n/a | n/a | n/a | 1.78 |
| Median of the others | US$292,268 | US$73,510 | 1.2× | 0.3× | 0.1× | −341.6% | 0.0× | 1.22 |
Team and board
Officers
| Officer | Role |
|---|---|
| Rebecca McQualter | Chief Executive Officer |
| Agathe Bourgogne | Head of Manufacturing |
| Stephanie H Astrow | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Bradley Glover | Non-executive Chair |
| Lesley Russel | Non-Executive Director |
| Miles Prince | Non-Executive Director |
| Philip Hains | Non-Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Aug 29, 2025 | 0.0% |
| Q2 2025 | Feb 28, 2025 | 0.0% |
| Q2 2023 | Feb 28, 2023 · Before open | −4.3% |
| Q4 2022 | Sep 30, 2022 · Before open | +1.1% |
| Q2 2022 | Feb 27, 2022 · After close | 0.0% |
| Q4 2021 | Aug 30, 2021 · After close | 0.0% |
| Q2 2021 | Feb 26, 2021 · After close | +1.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2026) | Investor deck | 19 slides | Jul 28, 2026 |
| Investor Presentation (March 2026) | Investor deck | 18 slides | Mar 25, 2026 |
| Shareholder Meeting (November 2025) | Shareholder meeting | 7 slides | Nov 25, 2025 |
| Investor Presentation (October 2025) | Investor deck | 24 slides | Oct 8, 2025 |
| Investor Presentation (September 2025) | Investor deck | 18 slides | Sep 9, 2025 |
| Shareholder Meeting (July 2025) | Shareholder meeting | 11 slides | Jul 23, 2025 |
| Investor Presentation (May 2025) | Investor deck | 14 slides | May 22, 2025 |
| Shareholder Meeting (December 2024) | Shareholder meeting | 11 slides | Dec 4, 2024 |
| Shareholder Meeting (November 2024) | Shareholder meeting | 15 slides | Nov 12, 2024 |
| Investor Presentation (July 2024) | Investor deck | 42 slides | Jul 25, 2024 |
All 23 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Shareholder Meeting (June 2024) | Shareholder meeting | 19 slides | Jun 11, 2024 |
| Investor Presentation (January 2024) | Investor deck | 41 slides | Jan 18, 2024 |
| Shareholder Meeting (November 2023) | Shareholder meeting | 13 slides | Nov 14, 2023 |
| Investor Presentation (October 2023) | Investor deck | 32 slides | Oct 25, 2023 |
| Shareholder Meeting (September 2023) | Shareholder meeting | 13 slides | Sep 13, 2023 |
| Shareholder Meeting (November 2022) | Shareholder meeting | 24 slides | Nov 15, 2022 |
| Technical Presentation (March 2022) | Technical | 16 slides | Mar 7, 2022 |
| Investor Presentation (February 2022) | Investor deck | 44 slides | Feb 22, 2022 |
| Corporate Update (December 2021) | Corporate update | 26 slides | Dec 1, 2021 |
| Shareholder Meeting (November 2021) | Shareholder meeting | 18 slides | Nov 22, 2021 |
| Corporate Update (November 2021) | Corporate update | 14 slides | November 2021 |
| ASCO 2021 | Conference | 7 slides | Jun 4, 2021 |
| Corporate Update (March 2021) | Corporate update | 20 slides | Mar 18, 2021 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Convertible notes with associated warrants Tranche closed: A$650,000 raised Use of proceeds: Support the ongoing Phase 1/2 clinical trial activities and general working capital | Jul 31, 2026 | US$456,561 |
| Private placement of fully paid ordinary shares with 1-for-1 attaching options Announced: A$4.4M · A$0.003 a share · Warrants at A$0.005 · PAC Partners Securities Pty Ltd +1 Dealers: PAC Partners Securities Pty Ltd (co-lead), Taylor Collison Limited (co-lead) Buyers: US-based family office (US$2 M (~A$3 M) commitment) Use of proceeds: CHM CDH17 CAR-T trial to end of Phase 1, CORE-NK clinical programs, working capital and offer costs | Dec 23, 2025 | US$2.94M |
| Convertible note Announced: A$4M Buyers: US institutional investor (A$4 M via Convertible Note) Use of proceeds: Fund the CHM CDH17 CAR-T trial through Phase 1, including next patient cohort at an increased dose | Dec 23, 2025 | US$2.68M |
| Rights offering of new fully paid ordinary shares with attaching options Closed: A$1M raised · 1 new attaching option for every New Share issued · PAC Partners +1 Dealers: PAC Partners (co-lead), Taylor Collison (co-lead) Use of proceeds: Further runway to progress the company's programs | Apr 24, 2025 | US$639,490 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in AUD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 3.97M | 7.46M | 4.51M | 2.62M | 2.65K | 0 |
| Cost of revenue | 846.8K | 3.92K | 965.4K | 949.8K | 847.0K | |
| Gross profit | 3.12M | 7.45M | 3.54M | 1.67M | -844.3K | |
| Research and development | 9.76M | 10.1M | 13.5M | 5.17M | 3.78M | |
| Selling, general and administrative | 7.05M | 9.00M | 11.9M | 8.73M | 6.02M | 151.8K |
| Operating income | -15.1M | -12.3M | -29.5M | -14.6M | -14.8M | -64.0K |
| Depreciation and amortization | 1.03M | 1.01M | 965.4K | 949.8K | 847.0K | 153.6K |
| EBITDA | -14.1M | -11.3M | -28.5M | -13.6M | -14.0M | 89.6K |
| Interest expense | 211.0K | 331.8K | 773.8K | 640.1K | 5.88K | 0 |
| Income before tax | -10.3M | -16.3M | -30.3M | -15.7M | -15.1M | -64.0K |
| Income tax | 110.8K | -3.75M | 92.8K | 163.7K | -257.9K | -153.6K |
| Net income | -10.4M | -12.5M | -25.9M | -15.9M | -15.1M | -64.0K |
| Earnings per share, basic | -0.77 | -1.80 | -5.98 | -4.42 | -4.64 | -0.02 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 5.76M | 3.05M | 5.37M | 18.4M | 22.4M | 100 |
| Receivables | 4.55M | 86.6K | 3.65M | 2.66M | 24.2K | |
| Inventory | 1 | -882.1K | ||||
| Current assets | 10.5M | 3.22M | 9.35M | 21.2M | 22.7M | 100 |
| Property, plant and equipment | 5.60K | 16.0K | 13.6K | |||
| Total assets | 21.6M | 15.3M | 22.4M | 34.9M | 36.5M | 100 |
| Accounts payable | 6.57M | 3.20M | 7.41M | 4.70M | 2.04M | |
| Current liabilities | 14.6M | 10.1M | 14.7M | 9.02M | 7.35M | 64.0K |
| Long-term debt | 0 | 3.68M | ||||
| Total debt | 3.59M | 3.68M | 34.0K | |||
| Total liabilities | 19.6M | 12.8M | 16.7M | 9.17M | 11.4M | 64.0K |
| Shareholders' equity | 1.97M | 2.47M | 5.66M | 25.7M | 25.1M | -63.9K |
| Shares outstanding | 13.5M | 6.96M | 4.33M | 3.60M | 3.26M | 3.43M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -7.28M | -7.54M | -16.3M | -13.2M | -8.84M | -34.0K |
| Capital spending | -1 | -7.55M | -112.2K | -537.9K | -5.31M | -16.3K |
| Free cash flow | -7.28M | 10.1K | -16.4M | -13.7M | -14.1M | -34.0K |
| Cash from investing | -112.2K | -577.9K | -5.30M | -5.31M | ||
| Cash from financing | 10.0M | 8.26M | 253.4K | 9.50M | 36.5M | 34.1K |
| Dividends paid | -2.31M | -4.05M | ||||
| Share buybacks | -572.0K | -1.20M | -88.8K | -1.31M | -2.72M | 100 |
| Change in cash | 2.70M | 690.3K | -16.0M | -4.03M | 22.4M | 100 |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Notification of cessation of securities - CHM | Oct 30, 2026 | Financing | ASX |
| Notice of Annual General Meeting/Proxy Form | Oct 29, 2026 | Meeting notice | ASX |
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 29, 2026 | Quarterly report | ASX |
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 29, 2026 | Quarterly report | ASX |
| Ceasing to be a substantial holder for CHM | Oct 8, 2026 | Ownership change notice | ASX |
| Notice of initial substantial holder for CHM | Oct 6, 2026 | Ownership change notice | ASX |
| Final Director's Interest Notice - LR | Oct 5, 2026 | List of directors | ASX |
| Final Director's Interest Notice - BG | Oct 5, 2026 | List of directors | ASX |
| Initial Director's Interest Notice - RM | Oct 5, 2026 | List of directors | ASX |
| FY2026 Annual Report, creditor update and Board changes | Sep 30, 2026 | Annual report | ASX |
All 128 filings
Cap table
Built by 6ix from Chimeric Therapeutics Limited’s releases · as of Jul 31, 2026
- Common shares
- 147,461,982
- Fully diluted
- 147,461,982
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 147,461,982 |
Warrants and options
| Lot |
|---|
| Warrants · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 147,461,982 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Agathe Bourgogne | Head of Manufacturing · Since at least Nov 5, 2026 |
| Bradley Glover | Non-executive Chair · Since at least Nov 5, 2026 |
| Lesley Russel | Non-Executive Director · Since at least Nov 5, 2026 |
| Miles Prince | Non-Executive Director · Since at least Nov 5, 2026 |
| Philip Hains | Non-Executive Director · Since at least Nov 4, 2026 |
| Rebecca McQualter | Chief Executive Officer · Since at least Apr 21, 2026 |
| Stephanie H Astrow | Chief Scientific Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Chimeric Therapeutics Limited.